Literature DB >> 7986220

Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response.

C Gabay1, F Gay-Croisier, P Roux-Lombard, O Meyer, C Maineti, P A Guerne, T Vischer, J M Dayer.   

Abstract

OBJECTIVE: To determine whether the lack of acute-phase protein (APP) response in numerous patients with polymyositis/dermatomyositis (PM/DM) is related to an imbalance between cytokines and cytokine inhibitors.
METHODS: Levels of C-reactive protein (CRP), interleukin-1 beta (IL-1 beta), tumor necrosis factor alpha (TNF alpha), IL-6, IL-1 receptor antagonist (IL-1ra), TNF soluble receptor 55 kd (sTNFR 55 kd), and sTNFR 75 kd were tested in the serum of 15 patients with PM/DM, 14 patients with spondylarthropathies (SPA), and 12 healthy blood donors. Serum IL-1 beta, TNF alpha, IL-6, IL-1ra, sTNFR were measured by specific immunoassays.
RESULTS: Serum levels of CRP were lower in PM/DM patients than in SPA patients. Normal or slightly elevated CRP values were found in 10 of the 15 PM/DM patients, 7 of whom had active myositis. Serum IL-6 levels were significantly higher in SPA patients than in PM/DM patients, whereas serum IL-1ra and sTNFR levels were significantly higher in PM/DM than in SPA patients. IL-1ra levels were particularly elevated in patients with active myositis and decreased in response to treatment.
CONCLUSION: These differences in cytokine levels, particularly IL-1ra, between PM/DM and SPA patients are indicative of distinct pathogenic mechanisms. High levels of IL-1ra may account for the weak APP response in some PM/DM patients. Our results suggest that measurement of IL-1ra, together with clinical examination, may provide useful information for the followup of PM/DM patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7986220     DOI: 10.1002/art.1780371206

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  25 in total

1.  Protective effect of recombinant human IL-1Ra on CCl4-induced acute liver injury in mice.

Authors:  Run-Zhi Zhu; Di Xiang; Chao Xie; Jing-Jing Li; Jian-Jun Hu; Hong-Lin He; Yun-Sheng Yuan; Jin Gao; Wei Han; Yan Yu
Journal:  World J Gastroenterol       Date:  2010-06-14       Impact factor: 5.742

Review 2.  Treatment of inflammatory myopathy: emerging therapies and therapeutic targets.

Authors:  Siamak Moghadam-Kia; Rohit Aggarwal; Chester V Oddis
Journal:  Expert Rev Clin Immunol       Date:  2015-08-27       Impact factor: 4.473

3.  Altered cytokine expression of peripheral blood lymphocytes in polymyositis and dermatomyositis.

Authors:  M Aleksza; A Szegedi; P Antal-Szalmás; B Irinyi; L Gergely; A Ponyi; J Hunyadi; S Sipka; M Zeher; G Szegedi; K Dankó
Journal:  Ann Rheum Dis       Date:  2005-04-13       Impact factor: 19.103

4.  Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein.

Authors:  C Gabay; M F Smith; D Eidlen; W P Arend
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

5.  Increased expression of vascular cell adhesion molecule 1 in muscle biopsy samples from juvenile dermatomyositis patients with short duration of untreated disease is regulated by miR-126.

Authors:  Erin Kim; Joan Cook-Mills; Gabrielle Morgan; Simone T Sredni; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2012-11

6.  A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis.

Authors:  Adam Schiffenbauer; Megha Garg; Christine Castro; Angelina Pokrovnichka; Galen Joe; Joseph Shrader; Imelda Victoria Cabalar; Sara Faghihi-Kashani; Michael O Harris-Love; Paul H Plotz; Frederick W Miller; Mark Gourley
Journal:  Semin Arthritis Rheum       Date:  2017-10-16       Impact factor: 5.532

7.  Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases.

Authors:  Mai Kawazoe; Kaichi Kaneko; Kotaro Shikano; Natsuko Kusunoki; Toshihiro Nanki; Shinichi Kawai
Journal:  Clin Rheumatol       Date:  2017-05-27       Impact factor: 2.980

8.  Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies.

Authors:  L G Rider; C M Artlett; C B Foster; A Ahmed; T Neeman; S J Chanock; S A Jimenez; F W Miller
Journal:  Clin Exp Immunol       Date:  2000-07       Impact factor: 4.330

9.  Serum levels of interleukin-1 receptor antagonist (IL-1ra) in thyroid cancer patients.

Authors:  Sebastian Niedźwiecki; Tomasz Stepień; Krzysztof Kuzdak; Henryk Stepień; Roman Krupiński; Daniel Seehofer; Nada Rayes; Frank Ulrich
Journal:  Langenbecks Arch Surg       Date:  2007-12-07       Impact factor: 3.445

10.  Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behçet's disease.

Authors:  Nurşen Düzgün; Ergin Ayaşlioğlu; Hüseyin Tutkak; Olcay T Aydintuğ
Journal:  Rheumatol Int       Date:  2003-11-05       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.